- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05715372
Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy (GEMLIFE)
Study Overview
Status
Conditions
Detailed Description
The long-term goal of this research is to create and implement lifestyle interventions that will prevent or delay morbidities associated with accelerated aging in the menopausal women. By the end of this year, it is estimated that approximately 50 million women will be in the menopausal phase of their life. Menopause is defined by the decline in estrogen levels and subsequent increase in inflammatory markers which are associated with multiple morbidities involving the brain, bone and cardiovascular systems. Various lifestyle changes have been found to prevent or decrease these morbidities. Hormone replacement therapy in the early years of menopause is also a known therapeutic modality for the treatment of menopausal symptoms. The investigators will evaluate if hormone replacement and lifestyle change will have an enhanced effect on the prevention of morbidity and mortality.
Telomeres are distinct structures found at the end of chromosomes. As women enter into menopause, which is the biomarker for aging, there is a shortening of the telomere length. Poor lifestyle factors which cause oxidative stress, can lead to poor cell replication and critical shortening of telomere length. Telomerase, an enzyme which aids in gene sequencing, also declines. Shortened telomere length and low levels of telomerase lead to cell aging and apoptosis, a reduction in normal organ function, and an increase in morbidity and mortality. It has been found that lifestyle intervention, and possibly hormone replacement, can enhance telomere length and telomerase production.
This research will focus on the acute menopausal woman (within 5 years of the last menstrual period), with and without hormone replacement, .and multiple lifestyle interventions. Early intervention within the first five years of menopause is most important in affecting long term morbidity and mortality in women. Serial measurement of various biomarkers and cytokines associated with aging, and measurements of telomere length and telomerase levels will be performed over a 9 month period of time. Evidence shows that diet, physical activity and cognitive intervention may synergize when combined in a multimodal intervention as each targets different mechanisms. The Investigators will evaluate the efficacy of each 12-week interventions on telomere length, telomere production, serum biomarkers and cytokine levels before and after each intervention, and as a multimodal approach. Approximately 100 women will be recruited once they have been confirmed to be in the early stages of menopause, then further divided based on the use of hormone replacement. Aims are to: (1) determine the independent and combined efficacies of lifestyle interventions on telomere length, (2) determine the independent and combined efficacies of lifestyle interventions on biomarkers and and cytokines, (3) Determine other mechanisms of aging associated with the acute phase of menopause . This key knowledge will aid in practical and early lifestyle interventions to deter detrimental morbidities in the menopausal women.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-hysterectomized women: Amenorrhea > 12 consecutive months
- Hysterectomized women: Bilateral oophorectomy (3 months after surgery)
- Normal mammogram in the past year
- Normal pap smear deemed to be negative within 5 years
- Able to understand the protocol and sign an informed consent
- Able to participate in a structured diet program for 12 weeks
- Able to participate in a structured walking program for 12 weeks
- Able to participate in a structured mindfulness-stress reduction program
- Able to operate an I-PAD, and able to connect to the internet
Exclusion Criteria:
- Known or suspected pregnancy
- Undiagnosed abnormal vaginal bleeding
- Known or suspected breast cancer or estrogen-dependent neoplasia
- Known or at risk for a MI, PE or significant cardiovascular event
- Poorly controlled blood pressure : sitting systolic > 160 or diastolic >95 mmHg
- Poorly controlled diabetes
- Uncontrolled thyroid disease
- Impaired liver function
- Unstable psychiatric disorder including depression or anxiety, PTSD
- History of drug or alcohol abuse
- Treatment with anticoagulants ( heparin, warfarin, lovenox, eliquis)
- Severe systemic disease which might interfere with interpretation of results
- Unwilling or unable to follow a diet, exercise or stress reduction protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Intervention group of menopausal women on hormone replacement
This group of women on hormone replacement will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
|
12-week structured program for Mediterranean diet.
12-week structured AHA walking program.
8-week structured mindfulness-based stress reduction (Cabot).
|
|
PLACEBO_COMPARATOR: Control group of menopausal women on hormone replacement
This group of women on hormone replacement will be given unstructured guidelines for diet, physical activity, and stress-reduction.
|
Unstructured 12-week program with basic outline for Mediterranean diet.
Unstructured 12-week walking program.
Unstructured program using mobile application for stress reduction.
|
|
ACTIVE_COMPARATOR: Intervention group of menopausal women without hormone replacement
This group of women will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
|
12-week structured program for Mediterranean diet.
12-week structured AHA walking program.
8-week structured mindfulness-based stress reduction (Cabot).
|
|
PLACEBO_COMPARATOR: Control group of menopausal women without hormone replacement
This group of women will be given unstructured guidelines for diet, physical activity, and stress-reduction.
|
Unstructured 12-week program with basic outline for Mediterranean diet.
Unstructured 12-week walking program.
Unstructured program using mobile application for stress reduction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Independent Lifestyle Interventions on Telomere Length
Time Frame: 12 months
|
Measurement of telomere length after 12 months of a Mediterranean diet, American Heart Association walking program, and mindfulness-based stress reduction program.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lifestyle Interventions on Inflammatory Biomarkers and Cytokines
Time Frame: 12 months
|
Inflammatory biomarkers ( C-Reactive Protein, WBC count) and cytokines (IL-6, TNFa)will be measured before 12 months of Mediterranean diet, the American Heart Association walking program and mindfulness based stress reduction
|
12 months
|
|
Measurement of Interventions on Inflammatory Biomarkers and Cytokines
Time Frame: 12 months
|
Inflammatory biomarkers C-Reactive Protein, WBC count)after 12 months after a Mediterranean diet, American Heart Association walking program and mindfulness based stress reduction program
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of Menopausal aging due to stress and inflammation of the microbiome
Time Frame: 12 months
|
Measurement of association between levels of cytokines (IL-6,TNFa)in the microbiome and telomere length
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20031704
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleNot yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health IndicatorsChile
-
University of NebraskaNot yet recruiting
-
Laboratorios Sophia S.A de C.V.CompletedOcular Inflammation | Ocular Pain | Pterygium | Post-surgical InflammationMexico
-
Ahmad ElheenyActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
Clinical Trials on Mediterranean diet
-
Purdue UniversityMushroom CouncilCompleted
-
Miguel López MorenoIMDEA Food; Hospital Clinico Universitario San Cecilio; Hospital Universitario...Not yet recruitingMetabolic Dysfunction-associated Liver DiseaseSpain
-
Coordinación de Investigación en Salud, MexicoEnrolling by invitationObstructive Sleep ApneaMexico
-
Penn State UniversityAlliance for Potato Research & EducationNot yet recruitingPrediabetes
-
Firat UniversityThe Scientific and Technological Research Council of TurkeyCompletedMediterranean Diet | Multiple Sclerosis (MS) - Relapsing-remittingTurkey (Türkiye)
-
Erasmus Medical CenterRecruitingAcromegaly Due to Pituitary Adenoma | Mediterranean Diet | Ketogenic DietNetherlands
-
University of East AngliaNewcastle UniversityCompletedDepression, AnxietyUnited Kingdom
-
University of California, IrvineCompletedPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Disorder | Myeloproliferative SyndromeUnited States
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
Parc de Salut MarRecruitingHIV Infection | Inflammation | Cardiovascular Risk | Mediterranean DietSpain